Papers using
Tissue Plasminogen Activator
antibodies
Papers on
Tissue Plasminogen Activator
Future directions of acute ischaemic stroke therapy.Saver et al., Boston, United States. In Lancet Neurol, Jul 2015
For several years, the only therapy with proven efficacy for acute ischaemic stroke was alteplase, which is approved for use within 4·5 h after stroke onset in many countries, but only within 3 h in the USA.
Thrombectomy within 8 hours after symptom onset in ischemic stroke.REVASCAT Trial Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Jul 2015
METHODS: During a 2-year period at four centers in Catalonia, Spain, we randomly assigned 206 patients who could be treated within 8 hours after the onset of symptoms of acute ischemic stroke to receive either medical therapy (including intravenous alteplase when eligible) and endovascular therapy with the Solitaire stent retriever (thrombectomy group) or medical therapy alone (control group).
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.SWIFT PRIME Investigators et al., Aş Şanamayn, Syria. In N Engl J Med, Jul 2015
BACKGROUND: Among patients with acute ischemic stroke due to occlusions in the proximal anterior intracranial circulation, less than 40% regain functional independence when treated with intravenous tissue plasminogen activator (t-PA) alone.
Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator.Nardi et al., Rio de Janeiro, Brazil. In Int J Mol Sci, 2014
Tissue plasminogen activator (tPA) mediates a number of processes that are pivotal for synaptogenesis and remodeling of synapses, including proteolysis of the brain extracellular matrix, degradation of adhesion molecules, activation of neurotrophins, and activation of the N-methyl-d-aspartate receptor.